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Title: The Natural History of Low Grade Squamous Intra-epithelial Lesions (LSIL) in 
Women attending  Groote Schuur Hospital Colposcopy Clinic                                                                                             
Author:    Dr K Govender                             Supervisor:    Prof L Denny                                           
Aims and Ojectives:                                                                                                                                  
To identify risk factors affecting rates of progression and regression of LSIL                                                                                                             
To determine the rates of progression and regression of disease in women with LSIL                              
To compare the natural history of LSIL in HIV positive and negative women                                             
To determine patient adherence to colposcopy clinic in women with LSIL                                          
Methods: This is a retrospective, descriptive, cohort study of women who were referred 
to the colposcopy clinic with a cytological diagnosis of LSIL and followed for a minimum 
period of 2 years.  Data was extracted from the colposcopy clinic data. Women who 
were referred and attended the clinic between 1st January 2009 and 31st December 
2013 were included in the analysis. Statistical analysis was performed using Stata 
version 13.1 (StataCorp LP,4905 Lakeway Drive,  College Station, TX 77845, USA).  . 
All p-values <0.05 were deemed statistically significant.                                                                                                                        
Results: The study population was 154 women with LSIL (N=154). Of these, 27 (17%) 
women were HIV negative, 106 (69%) were HIV positive and 18 had an unknown HIV 
status. The overall regression rate from LSIL to normality was 88.5% [95% CI = 83.9 – 
92.1%], with 128 of the 154 women having had regression of disease. The overall 
progression to higher grade lesions included 31 women, giving a progression rate of 




HIV positive women made up 69% of the study population but there was no significant 
difference in regression and progression between the HIV positive and negative women. 
The mean age of the group was 37.8 years with 60% of women screened at this clinic 
falling between 30-49 years of age. All age groups had similar trends of regression and 
progression, but those over 60 years of age were 12 times more likely to regress and 
none of them progressed to HSIL [p=0.002]. Those using an IUCD made up 141 
person-months studied, they were shown to have a 6 times greater likelihood to result in 
regression (p=0.01) compared to women on no contraception.  
 Conclusion: The high regression and low progression rates of LSIL are in keeping with 
global data and substantiate the need for surveillance rather than surgical intervention 
ie LSIL is a risk factor rather than a precursor for cervical cancer. The lack of difference 
in regression-progression rates despite HIV status means we can follow-up positive and 
negative women similarly (12 monthly). Older women (60+) are most likely over-called 
during diagnosis due to genital atrophy and thus follow-up interval can be longer than 
12 months. More research is required to assess IUCDs’ effect on LSIL regression and 















Cervical cancer is, world-wide, the fourth commonest cancer affecting women, behind 
breast, lung and colorectal cancer respectively. In 2012, an update of the Globocan 
datatabase, placed a global estimate of 529 512 cervical cancer cases diagnosed 
annually. Eighty six percent of these cases (n = 453 032) were diagnosed in developing 
countries1. It was estimated that 274 967 women died  from cervical  cancer in  the 
same year, of which 88% (n = 214 818)  were living in developing countries. The 
mortality to incidence ratio in developed countries was 36 - 43%. This was far lower 
when compared to developing countries where estimates of 54 - 80% have been 
reported1,2. This clearly highlights that cancer of the cervix is an important disease that 
causes significant morbidity and mortality on a global scale, particularly in low to middle 
income countries (LMICs). The tragedy of these statistics, both internationally but 
especially in developing countries, is that cervical cancer is a preventable condition. All 
invasive pathology is preceded by a precursor phase which is detectable through 









1.2 Histology of the cervix 
Most of the cervix is composed of fibromuscular tissue whilst the epithelium is either 
squamous or columnar in nature. The endocervix is lined by columnar epithelium that 
secretes mucus. It has has infoldings that resemble glands or clefts, although are not 
true  glandular structures. 
The ectocervix is covered by nonkeratinizing, stratified squamous epithelium, and has 
basal, midzone and superficial layers3. After menopause, these  layers become  
atrophic and may resemble  dysplastic cells which are characterized  by high  nuclear:to  
cytoplasmic ratios  and often lead to false positive  cytological diagnoses.  A  similar 
problem is encountered in  women who are hypoestrogenic,  including  prepubertal  
girls, who fortunately  rarely undergo cytological  screening.   
The squamo-columnar junction (SCJ) is where squamous and columnar epithelia meet. 
This junction can migrate depending on oestrogen status. Estrogen is responsible for 
depositing glycogen into squamous cells.  These cells are in a constant  state  of 
desquamation and the glycogen is  converted to lactic acid by the doderlein bacilli, 
natural commensals of the vagina.  The lactic acid is responsible for  the normal vaginal 
pH being  less than 4.5 and it is this acidity that is  believed  to stimulate  the process of 
metaplasia: a process whereby one  mature type of  epithelium is converted to another3.   
In the  case of the cervix, the exposed columnar epithelium is converted to squamous 
epithelium, creating the transformation zone. The transformation zone is the area 
between original SCJ and new SCJ, and is the site of  90% of squamous cell 




Basal cells are derived from SCJ cells, are cuboidal to low columnar with scant 


























Human Papilloma Virus (HPV) is a double stranded Deoxyribose Nucleic Acid (DNA) 
virus with over 100 subtypes. Approximately 40 of these are specific to the ano-genital 
region, some (like HPV 6 and 11) causing benign but morbid disease, whilst others (like 
HPV 16 and 18) are responsible for premalignant and malignant conditions. The virus 
particle, which is sexually transmitted through skin to skin contact, colonises the  





The natural history of cervical cancer has been studied extensively for the past 30 to 40 
years, and persistent infection of the cervix with certain high-risk types of HPV has been 
well established as a necessary cause of cervical cancer4. HPV is a very common 
sexually transmitted infection, usually acquired soon after initiation of sexual activity. 
Most HPV infections clear spontaneously within 1 to 2 years, but those that persist, 
particularly high-risk types of HPV (including HPV 16 and 18), may progress to cervical 
cancer precursors, and ultimately to invasive cervical cancer. High-risk types of HPV 
are identified in nearly all cancers of the cervix, and the relative risk of cervical cancer 
associated with persistent, ongoing infection with high-risk types of HPV is higher than 
the risk of lung cancer associated with smoking. Munoz and colleagues pooled data 
from 11 case-control studies involving 1,918 women with histologically confirmed 
squamous cell carcinoma of the cervix and 1928 control women5. The pooled odds ratio 
for cervical cancer associated with the presence of any HPV infection was 158.2 (95% 
CI: 113.4 – 220.6). On the basis of the pooled data, 15 HPV types were classified as 
high-risk (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) and are 
considered carcinogenic. The International Agency for Research on Cancer (IARC) 
includes the following types as Group One human carcinogens: 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, and 59. HPV 16 and 18 are responsible for about 70 percent of 
cases worldwide6. There is little geographic variation in the predominant HPV types 
associated with cervical cancer. 
 
 The virus may remain in an episomal state and in the majority of cases, is cleared by 




the nucleus of the  host epithelial cell, the control  of the cell cycle is altered, viral genes 
are expressed and epithelial cells begin proliferating and causing pathologic and 
morphological changes to the cell. These changes are seen on cytological examination 
of the cells and  after staining with the Papanicoloau stain and graded according to 
severity as low grade squamous intra-epithelial lesions (LSIL). high grade squamous 
intra-epithelial lesions (HSIL), invasive cancer and/or glandular abnormalities. 
 
HPV infection can be detected  by cytology as well as  by molecular  testing. In essence 
HPV infection of the cervix is a proxy for LSIL and should be seen  as a risk factor for 
cervical  cancer (as smoking is for lung cancer) but not  a  true cervical cancer 
precursor. Fortunately, most patients infected with  HPV or  with the diagnosis  of LSIL 
will regress spontaneously without any clinical consequences for the patient.  . However 
if infection of the cervix with high-risk types of HPV  persists, progression is HSIL or 
cancer is likely to occur.7  Once the basement membrane is breeched, causing stromal 
invasion,  progression to invasive cervical cancer occurs. HPV infection of the host cell, 
integration into host DNA, DNA replication, viral spread and evasion of host immunity 
are all mediated by proteins coded for by viral DNA. There are 7 early (E) proteins and 2 













Table 1:  HPV proteins and functions 
 
Protein Functions 
E1 mediates viral DNA replication 
E2 Controls viral transcription and DNA replication 
E4 regulates the expression of late genes 
E5 Enhances the activity of E6 and E7 and assists  to 
immune-response evasion 
E6  inhibits apoptosis 
E7 Inhibits apoptosis and assists in immune reponse 
evasion  
L1 Major capsid protein and very immunogenic 
L2 Minor capsid protein 
 (Fernandes JV, Araújo JMG, Fernandes TAAM, Biology and natural history of human papillomavirus 













1.4 Genetics and Immunology of Natural History 
The genital infection by HPV is transmitted by direct contact with skin or epithelium 
usually, but not exclusively via vaginal or anal intercourse. In their lifetimes, 
approximately 50%–80% of sexually active individuals, will acquire a genital HPV 
infection, with peak incidence being close to sexual debut7.   
Incubation periods are variable ranging from weeks to months to years. At this stage, 
the cell contains HPV and may lay dormant or have lower levels of infectious virus being 
produced and released. Higher levels of this occur in the active replication phase, which 
also has a variable duration but over time most individuals will develop an effective 
immune response, eliminating cells containing viral DNA and thus the virus itself8. Cell-




maintaining immunity against the virus. This immune response promotes regression of 
the intra-epithelial disease9. Approximately 10% to 20% of individuals will not effectively 
clear the virus and will develop persistent infection placing them at higher risk for 
progression and development of cervical carcinoma10.  
 
After the infection phase, infectious HPV is exclusively housed in an episomal state in 
the basal cells. This is called the maintenance phase, where the virus is maintained in 
the basal cells of epithelium with minimal viral gene expression present in the 
proliferating epithelium. This phase is primarily mediated by E6 and E7; and due to low 
episomal count and minimal genetic expression, immune response is minimal in this 
phase. 
 
During the differentiation-dependent phase, when HPV-infected cells leave the basal 
layer, they undergo differentiation, and high levels of viral protein synthesis are induced. 
By restricting viral protein synthesis to highly differentiated cells, there is a delay in the 
expression of viral antigens to locations, making HPV less susceptible to host 
immunity11.        
Finally, the shedding stage is reached where a putative late promoter activates the 
capsid genes (L1 and L2), allowing the viral particles to assemble in the host nucleus, 
just before the complete virions are released from the outer epithelial layers. This 
occurs during normal physiological desquamation, thus avoiding inflammation (ie host 




Persistence and DNA viral integration into the host cell leads to an increased risk of 
epithelial dysplasia because of the genomic instability. E5, E6, and E7 can induce 
cellular abnormalities: fusion between cells, aneuploidy, chromosomal instability, and 
abnormal centrosome reduplication resulting in abnormal numbers of centrosomes. 
There is also activation and inactivation of p53 and pRB family members respectively  
allowing for further chromosomal abnormalities13. 
 
 
1.5 Screening and Prediction 
 
With the introduction of the Papanicolau smear test (Pap) in the 1950s, cervical cancer 
rates declined by more than 60% in the United States14, and in Europe it declined by 
84% in Iceland, 50% in Finland, 34% in Sweden, 27% in Denmark and 11% in 
Norway15. Pap smears are cytology based tests looking for dysplastic cells of the 
transformation zone of the cervix. Depending on specific cellular features, a 
cytopathologist can grade such cells as normal or atypical. Atypical cells, in turn, may 
be categorized as HSIL or LSIL as previously described.  
Prior to the 1970’s, noninvasive intra-epithelial lesions of the cervix were classified us- 
ing a 4-tiered terminology: mild dysplasia, moderate dysplasia, severe dysplasia, and 
carcinoma in situ16. In the early 1970s, Richart17 introduced the concept that all 
precursor lesions were part of a spectrum of a single disease process: cervical 
intraepithelial neo-plasia (CIN) [refer figure 2]. This  ‘terminology chaos’ led to a large  




terminology. This new system combined clinically similar cytological and histological 
types into a number of broad categories, the most important being: LSIL (koiliocytic 
cytologic atypia and CIN 1) and HSIL (CIN 2 and 3)18. It is currently the universal 
standard when describing intra-epithelial lesions. Richart’s CIN nomenclature is still 
used for histological description but as the Bethesda classification has more clinical 
relevance due to difference in behavior between HSIL and LSIL, our study will be 
referring to HSIL and LSIL diagnoses for both cytology and histology. 
This study focuses on women referred to the Colposcopy clinic at Groote Schuur 
Hospitalclinic  with a cytological diagnosis  of LSIL and specifically to determine factors 
associated with regression or progression of LSIL lesions. This will help to better target, 
evaluate, and treat patients who are at highest risk of higher grade lesions and invasive 
cancer. Diagnostic and therapeutic measures triggered by abnormal cytology or 
colposcopy, which  include  cold knife conization, large loop excision of the 
transformation zone (LLETZ) procedures, laser excision of cervical lesions and  cautery 
to the cervix have been shown to be  associated with a number  of  complications which  
include acute and chronic perineal pain, sexual dysfunction such as dyspareunia, 
miscarriage and pre-term labour, reduced quality of life, and are an increased financial 
burden to patient and health facility19. 
If it were possible to predict the risk of a woman with an LSIL Pap smear progressing to 
an HSIL lesion or invasive cancer, it will improve patient experience by exposing less 
women to invasive procedures. This will also greatly reduce financial burden to the 
health care system. Newer and more sensitive screening laboratory tests have been 




specificity, are currently expensive and where introduced., positive HPV  DNA  tests   
have been seen to increase the number of women who are screened positive rather 
than decreasing them. This study has therefore been designed  to evaluate the value of 
risk prediction  formulae  in managing clinical outcomes. 
 
There is a precedent for using risk prediction formulae in order to use evidence based 
models for predicting outcomes, eg as physicians make use of age, BMI, cigarette 
smoking status, family history etc to evaluate cardio-vascular disease potential in their 
patients21. This helps him or her triage care and improve decision making. All of this is 
pre-empted by data available in the clinical history.  
Several risk factors have been shown to be associated with an increased risk for both 
the persistence and progression of precancerous lesions of the cervix. These include 
age, cigarette smoking, number of sexual partners, gravidity, number and regularity of 
Pap tests,  immune suppression (e.g., HIV infection/ long term corticosteroid use among 
others), and long-term use of oral contraceptives22. Can any one of or a combination of 
these factors be used to predict progression, regression and persistence potential of 
women with LSIL? 
 
 
1.6 South African cervical cancer policy  for colposcopic referral and risk factors  
for cervical cancer  precursors 
In sub-Saharan African countries, human papilloma virus (HPV) screening is not yet 




pilot projects23. This has led to the introduction of a South African HPV vaccination 
program as of 2014 aimed at 9-12 year old school girls.  
The South African national cervical cancer screening program offers 3 free Pap smears 
per lifetime to asymptomatic women, after the age of 30, 10 years apart for those who 
screen negative. If a low-grade abnormality is found, the smear is repeated after 6-12 
months. Referral threshold for colposcopy includes24: 
 3 consecutive atypical squamous cells of undetermined significance (ASC –US) 
 1 Pap described as ASC –H (i.e. ASCUS but HSIL not excluded) 
  2 consecutive low-grade squamous intraepithelial lesion (LSIL) 
 1 high-grade squamous intraepithelial lesion (HSIL) or macroscopically 
suspicious lesion 
 Any glandular abnormality in cytology is also a criterion for colposcopy referral. 
HIV infected women have been found to have a higher prevalence of HPV infection (up 
to 68%).25,26 For women known with HIV infection, the clinical guidelines for the 
management of HIV and AIDS in adults and adolescents advises 1 Pap smear at 
diagnosis of HIV and then every 3 years if normal, regardless of antiretroviral therapy 
(ART) status27. 
In South Africa, referral of HIV-positive women for colposcopy evaluation is encouraged 
after the first abnormal smear If a high-grade lesion is visualized the policy at the GSH 
colposcopy clinic is to perform an immediate excisional procedure (LLETZ or large loop 
excision of the transformation zone) or a punch biopsy is performed is there is doubt 
and only fi the biopsy confirms a high-grade abnormality, an excision procedure is 




as the entire lesion is visible, including the upper limit, HSIL is colposcopically 
confirmed, there is no evidence of a glandular lesion or of microinvasion. Cold knife 
cone excision (CKC) is performed in cases where there is suspected early invasive 
carcinoma, adenocarcinoma in situ, large lesions or distorted anatomy not suitable for 
LLETZ, a discrepancy between cytology and/or histology and colposcopy or where 
colposcopy and LLETZ are not possible. Many patients are treated solely on the 
combined assessment of the Pap and the colposcopy – so – called ‘see and treat’ 
approach. The LLETZ is performed without prior punch biopsy at the first visit, to avoid 
patients having to return to the clinic for extra visits. This is the usual approach of 
Groote Schuur Hospital Colposcopy Clinic. In young women where there is still a wish 
for future pregnancy, confirmatory biopsies are required before LLETZ or CKC. 
 
 
1.6.1  HIV 
It has been shown that there is an altered course of HPV infection and development of 
cancer in HIV-infected women as opposed to those who are not HIV-infected. There is 
an increased persistence of genital HPV infection due to the immune-compromised 
state28 and that cervical lesions are more likely to progress to high-grade lesions and do 
so more rapidly29. In addition, it has been reported that there are trends of lower HPV 
and LSIL rates in those who have initiated anti-retroviral therapy due to lower viral loads 
and thus greater immunity30. 
However, global opinion regarding regression and progression is not uniform with some 




higher grade lesions in women who are HIV positive31. This was similar to data 
published by Heard et al regarding HIV positive women infected with high risk HPV DNA 
types32. 
In South Africa, the MACH-1(Management of abnormal cytology in HIV-1 positive 
women) Trial, showed that HIV status alone could not predict the presence of high risk 
HPV DNA types and in this study, the only significant predictors of abnormal cytology 
were high viral loads and low CD4 counts in HIV positive women33. 
 
1.6.2    Smoking 
Cigarette smoking has always been known to be one of the leading preventable causes 
of death. There is convincing evidence that tobacco smoking causes cardiovascular 
disease, chronic lung disease, and several epithelial cancers including lung cancer34,35. 
There has been a rise globally in both the incidence and prevalence of cigarette 
smoking. This is seen particularly among younger women35. There is also evidence that 
it may interfere with regression of cervical precursor lesions, thus resulting in the 
persistence cervical abnormalities36. 
There are several mechanisms theories implicated in carcinogenesis and halted LSIL 
regression associated with cigarette smoking. One molecular theory involves direct 
exposure of cervical epithelial cell DNA  to nicotine and cotinine, or aromatic polycyclic 
hydrocarbons found in tobacco smoke with subsequent dysplasia and carcinogenesis37. 
Cervical mucus of smokers contains cigarette constituents and their metabolites such 
as benzo-a-pyrene (BaP). BaP causes HPV genome amplification which can increase 




that long-term nicotine exposure could affect persistent cellular proliferation, inhibition of 
apoptosis, and stimulation of vascular endothelial growth factor (VEGF), with increased 
microvessel density39. Smoking also results in abnormalities in systemic and peripheral 
immunity, eg. unbalanced production of pro- and anti-inflammatory cytokines, 
suppression of T lymphocyte activity, diminished numbers of T lymphocytes, and low 
levels of immunoglobulins. All of these can result in decreased numbers and activity of 
Langerhans cells in the cervix of smokers; cells which play an important role in averting 
carcinogenesis and eliminating dysplastic cells40. 
 
 
1.6.3   Contraception 
The risk of cervical dysplasia seems to vary with the type of contraceptive method in 
question.  There has been a multitude of research addressing the impact of oral 
contraception (OC) in HSIL and LSIL, cervical carcinoma in situ (CIS), and invasive 
cervical cancer (ICC) development. The majority found an increased risk of ICC and 
CIS associated with long-term (>5 years) OC use. A meta-analysis on the association 
between hormonal contraceptives and cervical cancer concluded that there was a linear 
dose-response relationship between the two, but that the relationship tends to 
disappear with time after OC cessation41. However, there is no relationship as yet seen 
between OC usage and LSIL42-44.   
Logically, it can be assumed that although not complete, barrier methods should provide 
some decrease in HPV infection rate. Consequently, barrier methods have been seen to 




Levonorgestrel implants and intra-uterine systems have only recently been widely 
available. Results of studies to date of these contraceptive methods display no 
association increased risk of cervical SIL, or risks of progression or regression46. 
 
1.6.4   Menopause 
A quarter of all women who are screened within the UK national cervical screening 
programme are over the age of 5047. Most of these women are menopausal and will 
thus have lower circulating serum oestrogen levels. A hypo-oestrogenic state in the 
cervical epithelium could result in possible cytological changes. These changes may be 
difficult for a cytopathologist to distinguish from dysplsia seen in LSIL48. A menopausal 
state also makes colposcopy difficult due to decreased collagen content and atrophy 
leading to unsatisfactory colposcopy more often than not. In addition, the thinner 
epithelium results in an aceto-white change that may mimic CIN, compounded by the 
lack of intracellular glycogen that may result in partial iodine negativity49. Also in the 
background of atrophy, the nucleus to cytoplasm ratio in the basal cells are similar to 











1.7   Patient adherence to colposcopy clinic 
Patients with abnormal pap smears who fit referral criteria (as previously discussed) are 
referred to a colposcopy clinic and this forms an integral part of cervical cancer 
screening programs. However, when patients fail to attend recommended colposcopy 
appointments, they are defined as non-compliant. This is a common problem on a 
global scale with rates varying from 0.4% to 47.3%50. 
A failure of recommended follow-up could result in not identifying HSIL timeously and 
thus potentially allowing  progression of premalignant lesions to cancer51. 
From a service point of view, non-adherence results in inefficient use of already scarce 
health care resources, thus elevating national and global expense52. 
Risk factors for non-adherence may include younger age; lack of knowledge 
about cervical screening and colposcopy; lower grade abnormalities; lack of child care, 














2. Material and Methods 
 
2.1  Aim 
To identify risk factors affecting rates of progression and regression of disease 
in women with LSIL  
 
 
2.2  Objectives 
1. To determine the rates of progression and regression of disease in    
   women with LSIL 
 
2. To compare the natural history of LSIL in HIV positive and negative    
   women 
 
3. To determine patient adherence to colposcopy clinic appointments in   











2.3 Study Design 
 
2.3.1  Sampling strategy and Study population: 
This is a retrospective, descriptive, cohort study of women who were referred to 
the colposcopy clinic with a cytological diagnosis of LSIL and followed for a 
minimum period of 2 years.  Data was extracted from the colposcopy clinic data 
base which captures all new and follow up patients referred to the clinic. Women 
who were referred and attended the clinic between 1st January 2009 (when the 




2.3.2  Sample Size: 
Since this was a descriptive study, the power of the study was not considered in 
sample size calculation, but rather the precision that the sample size will provide 
to estimate a given parameter of the population. Since many parameters are 
being investigated, it was decided the sample size should be decided on 









2.3.3 Inclusion Criteria  
The study included all women with LSIL whose data were entered onto the GSH 
data  base and who attended the GSH Colposcopy Clinic between January 
2009 to December 2013.  
 
 
2.3.4 Exclusion Criteria 
Those women who had too much missing data to be able to add to data analysis 




2.3.5 Variables extracted from database: 
1. Age of at each point of contact with the colposcopy clinic 
2. Menopause status and years of menopause at each point of contact 
3. Contraception type and years of use at each point of contact 
4. HIV status and years since diagnosis at each point of contact 
6. CD4 counts and trend over time 
7. Duration of ARV therapy  







2.3.6 Data analysis 
Data was collected from the Groote Schuur Hospital Colposcopy Clinic Data 
Base and after all exclusion criteria were met, included subjects were analysed 
by both actual number and as a product of their visits, expressed as patient-
months. Visits and laboratory results were consolidated to 6 monthly and yearly 
intervals for ease of analysis. At least 64% of our population were compliant for 
a minimum of 726 days. For this reason, we have chosen the time period of 726 
days to analyse and describe regression and progression trends. Histology 
results were used as the gold standard where available, but not all visits 
included a tissue biopsy for histology. In these cases, cytology results were 
used in data analysis. Regression was defined as subsequent histology an 
cytology showing no evidence of dysplasia or malignancy following and initial 
LSIL diagnosis. Progression was defined as subsequent histology and cytology 
showing either HSIL or malignancy following an initial LSIL diagnosis.  
Descriptions of individual parameters were expressed both in terms of absolute 
patient number, as well as the number of times the parameter was observed 
which may been more than once in a given patient (observations). 
Statistical analysis was performed using Stata version 13.1 (StataCorp LP,4905 
Lakeway Drive,  College Station, TX 77845, USA).  The distribution of continuous data 
was assessed graphically and using the Shapiro Wilk test.  Normally distributed data 
were summarised using means and standard deviations and analysed using parametric 
methods (independent or paired t-tests as appropriate, or analysis of variance for the 




interquartile ranges and analysed using non-parametric methods (Mann-Whitney-U-
tests or Wilcoxon signed rank tests for paired data as appropriate, or the Kruskal Wallis 
test for the comparison of 3 or more medians). Binomial 95% confidence intervals were 
used to report the precision of binary variables. Time-to-event data were explored 
graphically using Kaplan-Meier plots and log-rank tests, followed by Cox proportional 
Hazards regression to estimate Hazard Ratios and their respective 95% confidence 
intervals). All p-values <0.05 were deemed statistically significant. 
After univariate analysis of all variables were carried out, those deemed to be of most 
significance were entered into a multi-variate analysis. These included: 
 Age 
 HIV status 
 CD4 counts 
 Contraceptive status 
 
 
2.4 Ethical Consideration 
During this study all principles of the Declaration of Helsinki were upheld. 
Participation in this study did not affect patient management in any way. This 
was a retrospective study looking at patient information recorded in a data-base; 
patient names were replaced by a study number to ensure confidentiality. No 
patient contact occurred, and there was thus minimal risk to patients. Ethical 




been obtained in 2011 (HREC REF: 344/2011). In addition,  ethical approval 





Within the study period, 208 women met the criteria for inclusion due to referral with a 
LSIL Pap. Thirty nine women were excluded, however, due to an incorrect diagnosis 
entered into  the data  base upon referral and 15 were excluded due to large amounts of 
irretrievable data not amenable to analysis. This left a study population of 154 women 
with LSIL as the reason for the referral to the colposcopy clinic. Of this group, 27 (17%) 
women were HIV negative, 106 (69%) were HIV positive and 18 had an unknown HIV 
status. The study population generated 252 observations during which time there 223 
observations of regression from LSIL to normal, making the overall regression rate 
88.5% [95% CI = 83.9 – 92.1%]. One hundred and twenty eight of the 154 women had 
regression of disease to normal. The overall progression to higher grade lesions 
included 31 women and 48 observations giving a progression rate of 17.7% [95% CI = 










The following tables and figures contain descriptive statistics of patient population by 
HIV status, hazard ratios and Kaplan Meier curves for progression/regression. 
TABLE 2.1: Description of study population vs HIV status 
 HIV 
NEGATIVE 
HIV POSITIVE HIV 
UNKNOWN 
TOTAL 
AGE (in years) 
   < 30 
   30-39 
   40-49 
   50-59 
   60-69 






























   Pre-menopausal 















   None 
   Combined oral 
   Injectable 
   IUCD 

























SMOKING 3 (2) 17 (11) 1 (1) 21 (14) 
PROGRESSION 5 (3) 25 (16) 1 (1) 29 (18) 
REGRESSION 22 (14) 89 (58) 17 (11) 128 
(88) 
TOTAL 27 106 18 154 





HIV positive women made up 69% of the women included in this study. However, over a 
time period of 726 days, there was no significant difference found in both the regression 
(Table 2.2) and progression (Table 2.3) rates of HIV infected women as compared to 
those who were uninfected. HIV positive women were further sub-analysed with regard 
to CD4 counts and found to still have no discernable difference in regression and 
progression rates compared to their negative counterparts by CD4 count. 
Commencement of or duration of anti-retroviral therapy also did not alter the trends 
displayed. Regression and progression curves were not significantly different from those 
of women whose status was unknown compared to HIV infected and uninfected women. 
 
 
Table 2.2: Regression rate vs HIV negative women 
 Hazard Ratio P-value 95 % Confidence interval 
HIV positive 0.798 0.357 0.494 - 1.290 




Table 2.3: Progression rate vs HIV negative women  
 Hazard Ratio P-value 95 % Confidence interval 
HIV positive 1.240 0.662 0.473 - 3.245 






Regression  decreased with time, primarily in year one. Sixty five out of 89 HIV positive 
women who regressed (74%) did so in year 1. Similarly, 71% of HIV negative women 
and 69% of HIV unknown women who regressed, experienced regression in year 1. 
 
Figure 4.1: Regression by HIV Status 
 
Progression decreased with time in all 3 groups, but patterns differed. HIV positive 
women had equivalent progression in both year 1 and 2 but HIV negative and unknown 
women had greater progression in year 2 as compared to year 1. There was 1 
progression in the HIV unknown group which occurred after 422 days of surveillance 
and 3 of the 5 progressions in the HIV negative group (60%) occurred in the second 
year. Over a 2 year period however, all 3 groups had similar regression and 
progression. 
Both HIV status and CD4 counts were included as variables in a multivariate analysis 










The mean age of the group was 37.8 years with 60% of women  falling between 30-49 
years of age. All age groups had similar trends of regression, and showed greater 
regression in year 1 as opposed to year 2. Although regression was shown to decrease 
with time, the <30 age group displayer much higher regression as compared to other 














Figure 5.1: Regression by age 
 
Progression was shown to uniformly decrease over the 2 years among all age groups 
except in those 50 years and over, where none progressed to higher grade lesions. 
 
 




Overall, women between the ages of 60 to 69 showed the greatest regression, and 
were 12 times more likely to regress as compared to their under 30 counterparts 
[p=0.002] (Table 3) .  
Age was included as a variable in a multivariate analysis but showed no difference in 
results from univariate analysis. 
 
Table 3: Regression of different age groups as compared to women under 30 
years old 
AGE (years) Hazard Ratio P-value 95 % Confidence interval 
30-39 1.640 0.090 0.926 – 2.900 
40-49 1.861 0.058 0.979 – 3.537 
50-59 1.499 0.355 0.635 – 3.540 
60-69 11.831 0.002 2.577 – 54.745 














The study population contained 138 pre-menopausal women (89%), 13 post-
menopausal women (8%) and 3 with unknown menopausal status. By the second year 
of follow-up, information regarding the status of these 3 women was consolidated. 
Regression of both pre-menopausal and post-menopausal women decreased with time 
and patterns of regression were similar (figure 6.1). There was no significant difference 
in absolute regression between post-menopausal and pre-menopausal women ( 9 
events [69%] vs  101 events [73%] respectively). 
 
 
Figure 6.1: Regression by Menopausal status 
 
Progression patterns, however, were not similar: menopausal women had a significantly 
lower absolute progression (2 events [15%] vs 29 events [23%] p=0.04) but both groups 
had the same probability of progression after 726 days. It was also noted that there 
were no events of progression observed in post-menopausal women in the first year of 





Figure 6.2: Progression by Menopausal status 
 
Seventy of the 143 women (49 %) followed up with known contraceptive status did not 
consistently use any form of family planning. They made up a total of 58% of the total 
person-months observed in this study. The largest group using a contraceptive, were 
those using injectables (32%). A distant third included 19 women who were surgically 
sterilized. Six women were on oral contraception and only 2 had IUCD’s in situ. 
Table 4.1: Description of Contraceptive use 
Contraceptive Number of Patients (%) Person-months 
None 70 (48.9) 21934 
OCC 6 (4.2) 1737 
Injectables 46 (32.1) 11227 
IUCD 2 (1.4) 141 
Sterilisation 19 (13.3) 3798 





Although those using an IUCD  made up 141 person-months studied, they were shown 
to have 6 times greater likelihood to result in regression (p=0.01) compared to women 
on no contraception. The other forms of family planning displayed no significant 




Table 4.2: Regression vs No Contraceptive use 
 
Contraceptive Hazard Ratio P-value 95% Confidence Interval 
OCC 0.759 0.596 0.274 – 2.105 
Injectables 0.887 0.595 0.570 – 1.380 
IUCD 6.499 0.012 1.508 – 28.012 
Sterilisation  1.0254 0.080 0.589 – 1.881 
 
 
As we have already ascertained the overall progression rate of our study population, we 
can mathematically predict expected progression events of individual variables provided 
they do not proportionately differ from the overall rate. Table 4.3 highlights this factor 
and shows clearly that those using the IUCD only, oral contraceptive or those who had 
a tubal ligation recorded an expected number of events. However those on nil 
contraception recorded 36% less progression events than expected and those on the 




Duration of contraceptive use was sub-analysed revealing no significant difference in 
absolute  or patterns of regression or progression. 
Contraceptive type was included as a variable in a multivariate analysis but showed no 
difference in results from univariate analysis. 
 
 
Table 4.3: Observed Progression  vs Expected progression as per Contraceptive 
type 
Contraceptive Events expected Events observed 
None 14.16 9 
OCC 1.59 2 
Injectables 8.93 13 
IUCD 0.10 0 
Sterilisation 3.21 4 
                Chi2 =  4.20 












3.4 Cigarette Smoking 
Only 21 women (14%) were smokers. There were no statistically significant differences 
seen in patterns of, or variations away from expected events in both regression and 
progression.  
 
Figure 7.1: Regression by Cigarette smoking status 
After 726 days, the probability of progression in smokers was 0.05, whilst that of 
































Number of patients 
 
Figure 8: Adherence rates of women attending GSH Colposcopy clinic 
 
 
There were 277 women with LSIL who had at least one visit to the colposcopy clinic. Of 
these women, 28 (10%) did not revisit the clinic thereafter. Sixty four percent of the 





timeline used for our study’s analysis. Only 39 women followed up for 1000 days (+/- 3 
years), 14 women followed up for 1500 days (+/- 4 years), and 2 for 2000 days (+/- 5 
years).  The intended follow-up for a women who returns to normal pap smear is 3 
























Our study has found a high rate of regression (88%) and low rate of progression (17%) 
of LSIL, with none progressing to invasive carcinoma. This is in keeping with global 
data: regression rates range between 84-99%54 and progression rates range between 
1.2-26%55. These unequivocal rates suggest that intervention (surgical or otherwise) is 
unnecessary, as almost all will regress, with a small percentage progressing to HSIL 
which can then be treated. Hence, LSIL may be considered as a risk factor for HSIL 
rather than a pre-malignant lesion itself. In so doing, the complications of cervical 
surgery can be avoided in most patients with LSIL, avoiding especially fertility and 
pregnancy related adverse events. They can also benefit from a longer interval follow-
up. 
More than two thirds of our eligible patients were found to be HIV positive, far 
outnumbering their HIV negative counterparts (106 vs 27). The most reasonable 
explanation for this is that HIV positive women access the health services more 
frequently and it is policy to offer cytology to all HIV positive women in the Western 
Cape. Screening of HIV negative women is mostly opportunistic and sporadic and 
hence many eligible HIV negative or HIV status unknown women are not screened. One 
of the main reasons for offering screening to HIV positive women is the risk of increased 
HPV acquisition amongst HIV positive women28.  
Progression and regression  of LSIL, in our study, were not affected by HIV status, CD4 
count levels, or the use of anti-retroviral therapy. This finding conflicts with international 
literature which proposes lower rates of regression and higher rates of progression, 




product of HPV DNA integration into the host genome and is thus, more of a genetic 
disease than an immunity-based one. This, together with the fact that the HPV virus has 
several mechanisms of evading host immunity, renders HIV status to not be a 
seemingly major factor in LSIL regression and progression. Large studies by Massad, 
Denny and Heard do indicate that HIV does not affect the rates in question31-33. 
The mean age of our study population was 37.8 years with almost two thirds of them 
being between the ages of 30-49 years. This is expected for a colposcopy clinic, as the 
intended age of screening is 30-50 years of age, with most patients being referred 
between 30-40 years of age. All women under the age of 60, had no differences in 
regression and progression but those over the age of 60 had a significantly higher 
regression and none of these women progressed to higher grade lesions. There are 
similar results in our pre-menopausal versus post-menopausal groups, but becomes 
apparent when age stratified. We suspect the reason for this finding to be directly 
related to oestrogen exposure to cervical tissue. These women are menopausal with 
decreased circulating oestrogen leading to cervical atrophy. The atrophic cells, under 
microscope examination, can easily be confused for the atypia of LSIL lesions48,49. 
Thus, in the case of older women, rather than increased regression alone, there may be 
an element of over-call.  
All women attending the colposcopy clinic had several family planning methods 
available to them but almost half (N=70) were on no form of contraception at all. Those 
that did use contraception, mostly fell into the group using injectables (N=46). Only 2 
women used IUCDs but they were found to increase regression 6 fold, although the 




Injectables were shown to be associated with a decreased rate of progression, but 
again, more data is required to confirm that result and as yet there is no literature 
regarding this contraceptive method and its effect on LSIL. The sub-analysis of the 
contraception categories in general were limited by the small numbers in each group 
and lack of statistical significance. 
Only 14% of our study population were regular cigarette smokers, making them a 
subset that could not provide significant results. This low incidence of smoking in 
women is well recognised Sub-Saharan Africa56. Reasons for this include cultural 
background and paternalistic social structure. There is no peer influence to initiate and 
maintain cigarette smoking; and a broader social norm of unequal gender liberties  
where it is acceptable for males to use money on vices and necessary for females to 
use money for child and household responsibilities. It thus, does not seem that cigarette 
smoking plays a great role in cervical dyplasia in Sub-Saharan Africa. 
Our patients’ 1-year adherence rate was 85%, far better than any global data on 
colposcopy clinic adherence50. However, this tends to decrease exponentially. A 2-year 
adherence rate of 64% is well within global standards, but a 14% 3-year adherence rate 
is far from satisfactory and needs to be addressed. Specific factors need to be isolated 
so that they can be acted upon to improve this rate. Factors we suspect may be 
implicated are those of, transport, finance, lack of education or miseducation, fear of 
invasive examination, lack of understanding regarding treatment and follow-up of an 
‘asymptomatic disease’. One must also allow for bias of patient selection, as many were 
excluded due to previously stated exclusion criteria and their follow-up data may change 




5. Reccommendations  
As discussed earlier, high rates of regression and low rates of progression of LSIL 
found in our study, allow us to recommend that all women with persistent  LSIL (3 
papsmears 6 - 12 months) apart should be offered follow up colposcopy and only 
treated once they have developed a HSIL lesion. Follow up can take place at intervals 
of 12 months until she has normal cytology and remains so for the next 3 - 5 years. She 
can then resume routine screening protocol.  There is no need for therapeutic 
intervention but a biopsy can be taken initially to confirm on histology or if unsure of the 
grade of dysplasia on colposcopy.  
As shown by our study, HIV status, CD4 counts, or even the use of anti-retroviral 
therapy does not appear to impact on LSIL regression or progression, and hence there 
should be no difference in management protocol of LSIL between this groups. 
Twelve monthly intervals of follow-up can even be lengthened to 3-yearly or 5-yearly in 
women above 60 as they tend to regress much faster and none have been seen to 
progress. To help the pathologist distinguish between atrophic cells and LSIL, this 
information must be provided with the specimen and local oestrogen therapy can be 
used if not contra-indicated prior to repeat cytology. 
Family planning must be encouraged in the colposcopy clinic as half of its attendants 
are not on any, and this is of particular significance for HIV positive women, who need 
to be encouraged to use dual contraception. . More research is required regarding the 
roles of IUCD’s and injectables on regression and progression respectively, before 




Lack of compliance of the patients is worrying with only 64% making the 2-year follow-
up. There are several factors, patient and institutional, which may contribute to this 
outcome but our database was not structured to address this issue. The fact that 15%  
of our study population did not follow-up for at least 1 year, and 36% for at least 2 years, 
limits our study in terms of results, conclusions drawn and recommendations. We do not 
know what the progression and regression were in these non-compliant groups and if 
they would change our results. A detailed, prospective study looking at factors 
impacting on adherence is necessary. Once these factors are known, they can be 
addressed and adherence rates improved. Thereafter, if the results of this study are 




This study, being retrospective in nature, carried with it, its own limitations. There were 
some statistics that could not be measured. Although variables were assessed to the 
best of our ability in a dynamic process, the temporal relationship, at times, was difficult 
to assess. As with all retrospective studies, exposure or outcome assessment cannot be 
controlled, but instead need to rely on others for accurate record-keeping.  
In addition, missing data greatly impeded our analysis, and in some cases there was 
just too much missing data to successfully analyse and these patients had to be 
excluded. 
A few of our subset populations were small and did not yield significant results. These 




Patient compliance played the largest factor in data analysis, as we only had 60% of the 
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